Beta-blockers in the treatment of cardiovascular disease
========================================================

Cardiovascular disease (CVD) is the leading cause of morbidity and mortality, accounting for 30% of all deaths worldwide ([@b80-vhrm-4-1387]). In the United States alone, CVD accounted for more than 36% of all deaths in 2004 or 1 of every 2.8 deaths ([@b2-vhrm-4-1387]). Blood pressure and CVD risk are directly proportional. In fact, mortality from ischemic heart disease and stroke doubles for every 20-mmHg increase in systolic blood pressure (SBP) or 10-mmHg increase in diastolic blood pressure (DBP) ([@b13-vhrm-4-1387]). Furthermore, hypertension is often an antecedent to heart failure and myocardial infarction (MI). High blood pressure (\>140/90 mmHg) has been identified in approximately 69% of Americans who have suffered a first MI and 74% of patients with chronic heart failure ([@b65-vhrm-4-1387]). Therefore, it is not surprising that successful treatment of hypertension has been shown to reduce the risk of stroke, coronary artery disease (CAD), and congestive heart failure, as well as overall cardiovascular morbidity and mortality ([@b3-vhrm-4-1387]). However, optimal treatment benefits will not be observed unless patients adhere to their prescribed treatment regimens.

Adherence to prescribed medication regimens has been shown to be highest with once-daily dosing in several disease areas, and to decrease as the number of daily doses increase ([@b14-vhrm-4-1387]; [@b23-vhrm-4-1387]). In fact, decreased adherence to a medication regimen was shown to contribute to up to 64% of rehospitalizations in patients with heart failure ([@b40-vhrm-4-1387]; [@b23-vhrm-4-1387]). However, tolerability also influences patient adherence to a medication regimen ([@b77-vhrm-4-1387]; [@b12-vhrm-4-1387]).

Beta-blockers have a long history in the treatment of hypertension and cardiac dysfunction, with more than 40 years of clinical use ([@b27-vhrm-4-1387]). However, concerns have been raised recently from hypertension meta-analyses regarding suboptimal outcomes with use of beta-blockers, specifically atenolol, compared with outcomes for other antihypertensive drug classes ([@b41-vhrm-4-1387]; [@b10-vhrm-4-1387]). Beta-blockers have also been associated with tolerability issues and concerns regarding negative effects on glucose and lipid metabolism. However, it should be noted that not all beta-blockers are identical, as differences in mechanism of action may translate into diverse efficacy and safety profiles ([@b26-vhrm-4-1387]; [@b27-vhrm-4-1387]).

Carvedilol is a third-generation, vasodilatory beta-blocker that nonselectively blocks both the beta 1- and beta 2-adrenergic receptors and, in addition, has alpha 1-adrenergic receptor-blocking activity. Unlike traditional beta-blockers (eg, atenolol, metoprolol, and propranolol) that lower blood pressure by reducing cardiac output ([@b55-vhrm-4-1387]), vasodilatory beta-blockers can lower blood pressure by reducing systemic vascular resistance (SVR) ([@b68-vhrm-4-1387]). As with other beta-blockers, carvedilol has been shown to reduce sympathetic nervous system (SNS)-mediated cardiac stress and myocardial hypertrophy ([@b71-vhrm-4-1387]). These activities likely contribute to the clinical benefits observed in patients treated with carvedilol for hypertension, heart failure, and post-MI left ventricular dysfunction (LVD). Moreover, the regimen of twice-daily carvedilol has been associated with a favorable side effect and tolerability profile.

In order to improve adherence to therapy and to ease the pill burden on patients, a controlled-release formulation of carvedilol (carvedilol CR) was developed and is approved for use in the same indications (ie, hypertension, heart failure, and post-MI LVD) as immediate-release (IR) carvedilol. This review presents an overview of the clinical and pharmacologic carvedilol CR data.

Pharmacology of carvedilol
==========================

Mechanism of action
-------------------

Traditional beta-blockers either selectively antagonize beta 1-adrenergic receptors (selective beta-blockade) or antagonize both beta 1- and beta 2-adrenergic receptors (nonselective beta-blockade). Although beta 1-selective agents are cardioselective, selectivity is dose dependent, and at high doses beta 1-selective agents may also antagonize beta 2-adrenergic receptors ([@b21-vhrm-4-1387]). Traditional beta-blockers reduce blood pressure primarily by decreasing cardiac output, and systemic vascular resistance is usually unchanged ([@b47-vhrm-4-1387]). Inhibition of norepinephrine binding to beta-adrenergic receptors results in decreased heart rate and myocyte contractility ([@b55-vhrm-4-1387]).

Unlike traditional beta-blockers, carvedilol blocks norepinephrine binding to alpha 1-adrenegric receptors as well as beta 1- and beta 2-adrenegeric receptors ([@b60-vhrm-4-1387]). Alpha 1-adrenergic receptors mediate vasoconstriction. Consequently, alpha 1-blockade results in vasodilation of the peripheral arteries, decreasing SVR ([@b55-vhrm-4-1387]; [@b22-vhrm-4-1387]). In addition, preclinical evidence suggests that carvedilol can also produce nitric oxide-mediated vasodilation ([@b37-vhrm-4-1387]).

Carvedilol does not possess intrinsic sympathomimetic activity ([@b71-vhrm-4-1387]). Intrinsic sympathomimetic activity induces weak stimulation of the beta-adrenergic receptors that may dampen the positive effects of beta 1-adrenergic receptor blockade ([@b21-vhrm-4-1387]; [@b27-vhrm-4-1387]). Of note, beta-blockers with intrinsic sympathomimetic activity have failed to demonstrate reductions in morbidity and mortality in patients with heart failure ([@b42-vhrm-4-1387]).

Carvedilol has also demonstrated antioxidant effects possibly attributable to stimulation of endothelial nitric oxide production or reduced nitric oxide inactivation ([@b71-vhrm-4-1387]). Furthermore, carvedilol may protect against reactive oxygen species (ROS) through scavenging of free radicals, suppression of free radical generation, and prevention of ferric ion-induced oxidation ([@b71-vhrm-4-1387]; [@b18-vhrm-4-1387]). The ability of carvedilol to scavenge free radicals has been correlated with improved outcomes in patients with heart failure and a recent MI ([@b30-vhrm-4-1387]). In a study involving 39 patients with heart failure and a recent MI, carvedilol IR was shown to decrease oxygen free radical measurements using thiobarbituric acid reactive substances assay, thermochemoluminescence, and conjugated dienes methodologies in 29 patients (irrespective of dosage) after 6 months of treatment ([@b30-vhrm-4-1387]). This decrease correlated with increased heart function (6-minute walk test; baseline, 332 m and at 6 months, 397 m; p \< 0.05) compared with patients who had no evidence of reduced oxygen free radical measurements (6-minute walk test; baseline 326 m and at 6 months, 317 m; r = 0.83; p \< 0.01) ([@b30-vhrm-4-1387]). Moreover, patients with reduced oxygen free radical measurements had improved clinical outcomes within 1 year compared with patients who had no reduction (chronic heart failure hospital readmissions, 10% versus 50%, respectively; p \< 0.01) and death rates (3% versus 20%, respectively; p \< 0.01) ([@b30-vhrm-4-1387]).

Antioxidant activities decrease elevated oxidative stress, which, in turn, reduces lipid peroxidation. Reduced lipid peroxidation may contribute to protection from myocardial and brain cell ischemic death in patients with hypertension, heart failure, ischemic heart disease, diabetes, and renal dysfunction ([@b43-vhrm-4-1387]; [@b29-vhrm-4-1387]; [@b49-vhrm-4-1387]; [@b50-vhrm-4-1387]; [@b58-vhrm-4-1387]). Anti-oxidant activities of carvedilol may also inhibit low-density lipoprotein (LDL) oxidation, which could decrease accumulation of oxidized LDL in vessel walls ([@b43-vhrm-4-1387]). In patients with heart failure, free fatty acid levels become elevated (possibly from SNS hyperactivity) and the myocardial rate of fatty oxidation may increase; however, during disease progression, myocardial energy efficiency is increased through a compensatory shift from the free fatty acid substrate to glucose ([@b67-vhrm-4-1387]). Preliminary clinical evidence suggests that pharmacologic treatments facilitating the compensatory metabolic switch at an earlier stage of disease may provide mortality benefits ([@b67-vhrm-4-1387]). Indeed, carvedilol has demonstrated decreased myocardial use of free fatty acids and either increased or neutral effects on myocardial glucose use in patients with heart failure ([@b76-vhrm-4-1387]; [@b61-vhrm-4-1387]; [@b1-vhrm-4-1387]).

Carvedilol is also known to have anti-inflammatory properties. Inflammation has been linked to the pathogenesis of heart failure and atherosclerosis ([@b82-vhrm-4-1387]; [@b69-vhrm-4-1387]). In a clinical trial in patients with hypertension and diabetes, carvedilol IR (12.5 mg twice daily) reduced pro-inflammatory markers, including plasma C-reactive protein and monocyte chemotactic protein-1 ([@b18-vhrm-4-1387]). Furthermore, carvedilol has been shown to decrease serum concentrations of the inflammatory cytokines IL-6 and TNF-α in patients with ischemic and nonischemic dilated cardiomyopathy ([@b38-vhrm-4-1387]).

In addition, carvedilol has been shown to stimulate beta-arrestin signaling ([@b79-vhrm-4-1387]). Beta-arrestin is involved in the desensitization process of β-receptors in response to catecholamines and is implicated in G protein-mediated cardiac remodeling in heart failure ([@b39-vhrm-4-1387]; [@b59-vhrm-4-1387]). Recent results in animal models suggest that beta-arrestin G protein-independent signaling may also occur and provide cardioprotective effects ([@b59-vhrm-4-1387]). Furthermore, work is currently underway using beta-arrestin agonists such as carvedilol to form "super" beta-blockers that can turn off G protein-mediated signaling of the beta-receptor but still maintain the benefits of continued β-arrestin-mediated signaling on cell survival systems ([@b79-vhrm-4-1387]).

Pharmacokinetics and pharmacodynamics
-------------------------------------

Carvedilol CR was developed to achieve sustained concentrations over a 24-hour period, allowing once-daily dosing. The pharmacokinetic and pharmacodynamic bioequivalence of carvedilol CR and IR was established through 2 clinical studies ([@b33-vhrm-4-1387]; [@b57-vhrm-4-1387]). In a double-blind, parallel-group, crossover study, 122 patients with essential hypertension were randomized to receive either low-dose carvedilol CR (20 mg daily) or carvedilol IR (6.25 mg twice daily), high-dose carvedilol CR (80 mg once daily \[initiated at 20 mg once daily and titrated to 40 mg and 80 mg once daily in 1-week intervals\]) or carvedilol IR (25 mg twice daily \[initiated at 6.25 mg twice daily and titrated to 12.5 mg and 25 mg twice daily in 1-week intervals\]), or placebo ([@b33-vhrm-4-1387]). After 22 days of treatment, patients were crossed over to the equivalent alternate carvedilol formulation for 8 days of treatment. Patients in the placebo treatment group continued to receive placebo throughout the study. Pharmacokinetic parameters were assessed at the end of each treatment session. The pharmacodynamic endpoint was the percentage change from baseline in exercise-induced heart rate. As carvedilol is a racemic mixture of R(+) and S(−) enantiomers ([@b51-vhrm-4-1387]), both forms were assessed in the pharmacokinetic analysis. The pharmacokinetic profiles of both enantiomers were equivalent between carvedilol CR and IR ([Figure 1](#f1-vhrm-4-1387){ref-type="fig"}) ([@b33-vhrm-4-1387]). In addition, both formulations maintained a reduced exercise-induced heart rate over a 24-hour period ([@b33-vhrm-4-1387]).

In a separate 4-week study, patients with either mild to severe heart failure or with asymptomatic post-MI LVD were treated with the carvedilol IR (3.125, 6.25, 12.5, or 25 mg twice daily) for the first 2 weeks and then switched to carvedilol CR (10, 20, 40, or 80 mg once daily) for 2 weeks ([@b57-vhrm-4-1387]). Trough plasma concentration, maximum plasma concentration, and area under the curve was measured for both R(+) and S(−) enantiomers after carvedilol IR and CR treatment periods. The pharmacokinetics of carvedilol IR and CR were bioequivalent in patients with heart failure and post-MI with LVD. However, the median time to maximum observed plasma concentration for carvedilol CR lagged 3 hours behind that of carvedilol IR, in accordance with the prolonged-release characteristics expected in a once-daily formulation. The pharmacodynamics of carvedilol CR were dose proportional over the dose range tested (10 mg to 80 mg) ([@b57-vhrm-4-1387]).

Notably, the bioavailability of carvedilol CR is 85% that of carvedilol IR ([@b70-vhrm-4-1387]). Carvedilol CR is based on carvedilol phosphate, which has a higher molecular weight than carvedilol free base and contains additional carvedilol free base compared with carvedilol IR to adjust for bioavailability. This difference contributes, in part, to slightly higher milligram dosage strengths of carvedilol CR than the "equivalent" carvedilol IR doses ([@b70-vhrm-4-1387]). A model of carvedilol pharmacokinetics that takes into consideration both the IR and CR formulations has been developed and performed robustly in leverage analyses ([@b52-vhrm-4-1387]). Similar to carvedilol IR, the bioavailability and pharmacokinetics of carvedilol CR are influenced by food, and both formulations are recommended to be taken with food ([@b70-vhrm-4-1387]). However, the pharmacokinetics of carvedilol CR 40 mg were not affected by ethanol (38 g) intake from 2 hours before to 2 hours after dosing in 39 healthy volunteers ([@b34-vhrm-4-1387]).

Implications of mechanism of action on metabolic effects and vascular health
----------------------------------------------------------------------------

Poor glycemic control predicts cardiovascular events; in particular, glycosylated hemoglobin levels linearly correlate with the risk of cardiovascular complications in patients with type 2 diabetes ([@b16-vhrm-4-1387]; [@b44-vhrm-4-1387]). Moreover, dyslipidemia is a common comorbid condition in patients with hypertension ([@b36-vhrm-4-1387]). Men with a serum cholesterol level greater than 253 mg/dL have been shown to have a relative risk of CAD 3.8 times greater than men who had levels less than 181 mg/dL ([@b66-vhrm-4-1387]). Traditional, nonvasodilating beta-blockers have been associated with worsening of glycemic control and impaired lipid metabolism ([@b7-vhrm-4-1387]). In contrast, because of its vasodilatory mechanism of action, which facilitates muscle uptake of glucose and increases the availability of lipoprotein lipase, carvedilol does not negatively affect glycemic control or lipid profile compared with metoprolol ([@b47-vhrm-4-1387]). Carvedilol CR is currently being studied in a randomized, double-blind clinical trial comparing lipid effects of metoprolol succinate extended release with carvedilol CR in patients with hypertension and either normal lipids or mild dyslipidemia ([@b8-vhrm-4-1387]). The primary endpoints are the change from baseline in HDL-C and in triglycerides after 6 months of treatment. Several other trials have reported on glucose and lipid metabolism parameters using carvedilol IR and results have generally demonstrated improved profiles compared with metoprolol ([@b6-vhrm-4-1387]; [@b11-vhrm-4-1387]; [@b73-vhrm-4-1387]).

The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial compared the effects of carvedilol IR (6.25 mg to 25 mg twice daily) with metoprolol (50 mg to 200 mg twice daily) on glycemic control and lipid profile in 1235 patients with diabetes and hypertension ([@b6-vhrm-4-1387]). After 5 months of treatment in this randomized, double-blind, parallel-group trial, carvedilol IR did not increase HbA~1c~ (0.02%; p = 0.65), whereas metoprolol significantly increased HbA~1c~ levels from baseline (0.15%; p \< 0.001) ([Figure 2](#f2-vhrm-4-1387){ref-type="fig"}). Moreover, a greater number of patients withdrew because of worsening glycemic control in the metoprolol group (2.2%) compared with the carvedilol group (0.6%; p = 0.04). These data support the results of an earlier comparison study of metoprolol and carvedilol, which found that insulin sensitivity increased with carvedilol and decreased with metoprolol treatment ([@b35-vhrm-4-1387]).

Comparison of lipid parameters showed that carvedilol IR decreased total serum cholesterol levels to a greater extent than metoprolol (between-group difference, −2.9%; p = 0.001) in the GEMINI study ([@b6-vhrm-4-1387]). Carvedilol IR also decreased LDL cholesterol (LDL-C) compared with metoprolol (between-group difference, −1.3%; p = 0.40). In contrast with metoprolol, carvedilol did not significantly increase mean triglyceride levels. As kidney damage is a substantial concern for patients with hypertension and/or diabetes, kidney function was also measured in this study. Significant reductions in albumin secretion (16% relative reduction; p = 0.003) and progression to overt microalbuminuria were observed with carvedilol compared with metoprolol (p = 0.04).

The neutral effects of carvedilol on glycemic control and lipid metabolism have also been established in patients post-MI. Fifty-nine patients post-MI were randomized to add either metoprolol (100 mg twice daily) or carvedilol IR (25 mg twice daily) to their currently prescribed regimen for 12 weeks ([@b11-vhrm-4-1387]). After 12 weeks, patients receiving metoprolol had a significantly increased homeostasis model for insulin resistance (HOMA-IR), whereas carvedilol treatment significantly decreased HOMA-IR (p \< 0.05 compared with baseline). In addition, carvedilol IR significantly decreased total cholesterol and LDL-C levels when compared with metoprolol (p = 0.043 and p = 0.021, respectively).

Treatment with carvedilol IR has been shown to reduce the incidence of diabetic events and new-onset diabetes among patients with heart failure. In the Carvedilol Or Metoprolol European Trial (COMET), 3029 patents with chronic heart failure were randomly assigned to treatment with target daily doses of carvedilol IR 50 mg or metoprolol tartrate 100 mg ([@b73-vhrm-4-1387]). In a cohort of 2298 patients without diabetes at trial initiation, diabetic events (adverse events of diabetic coma, peripheral gangrene, diabetic foot, decreased glucose tolerance, or hyperglycemia) and new-onset diabetes (clinical diagnosis, repeated high random glucose level, or glucose-lowering drugs) were assessed. Over a 5-year period, fewer diabetic events were reported with carvedilol IR (122 of 1151 patients; 10.6%) versus metoprolol (149 of 1147 patients; 13.0%; p = 0.039). New-onset diabetes (investigator reported) was also significantly less prevalent in the carvedilol IR treatment group (119 patients; 10.3%) compared with the metoprolol treatment group (145 patients; 12.6%; p = 0.048)

Efficacy of carvedilol in cardiovascular disease
================================================

The majority of clinical data for carvedilol come from studies with the IR formulation. However, several studies, both of bioequivalence and efficacy, have been conducted with carvedilol CR ([@b70-vhrm-4-1387]; [@b78-vhrm-4-1387]). Carvedilol CR is indicated for the treatment of hypertension, mild to severe heart failure, and post-MI LVD -- the same indications as carvedilol IR. Data presented in this section are a mixture of carvedilol IR and CR studies.

Hypertension
------------

The efficacy of carvedilol CR in the treatment of hypertension was established in a double-blind, parallel-group trial in which patients with essential hypertension (N = 338) were randomized to receive carvedilol 20, 40, or 80 mg or placebo once daily after a 4-week washout period ([@b77-vhrm-4-1387]; [@b78-vhrm-4-1387]). Change from baseline in DBP measured by 24-hour ambulatory blood pressure monitoring after 6 weeks of treatment was the primary endpoint ([@b77-vhrm-4-1387]). The patient population consisted of a mixture of patients, including those who were not receiving antihypertensive treatment, those with controlled hypertension (DBP \< 90 mmHg) who were receiving antihypertensive treatment at baseline, and those with uncontrolled hypertension (DBP ≥ 90 mmHg) despite treatment with ≤2 non-beta-blocker antihypertensive agents at baseline. Mean sitting SBP and DBP at baseline were 150 mmHg and 99 mmHg, respectively, indicating a population with stage 1 hypertension ([@b13-vhrm-4-1387]). Placebo-adjusted change from baseline in 24-hour DBP was −4.03, −7.56, and −9.19 mmHg, respectively, with carvedilol CR 20, 40, and 80 mg (p ≤ 0.001) ([@b77-vhrm-4-1387]). Significant reductions in placebo-adjusted 24-hour SBP were also observed (−6.12, −9.43, and −11.85 mmHg, respectively) ([@b78-vhrm-4-1387]). Carvedilol CR treatment resulted in significant, dose-dependent reductions in peak and trough blood pressure measurements ([Figure 3](#f3-vhrm-4-1387){ref-type="fig"}). Blood pressure control, defined as DBP \< 90 mmHg, was achieved by 45% to 53% of patients treated with carvedilol compared with only 15% of patients who received placebo. Pulse pressure was assessed via an ad hoc analysis and was significantly reduced with carvedilol versus placebo (p \< 0.05).

These data build on the established safety and efficacy of carvedilol IR in the treatment of hypertension demonstrated in several US and international placebo-controlled trials. In patients with hypertension, carvedilol IR has been shown to reduce blood pressure and exercise and resting heart rates ([@b60-vhrm-4-1387]). Blood pressure reductions are likely linked to reductions in SVR in addition to the other BP-lowering properties of all beta-blockers, which have been demonstrated in healthy volunteers treated with carvedilol IR ([@b68-vhrm-4-1387]).

The antihypertensive efficacy of carvedilol has been reported in patients with hypertension and comorbid conditions, such as diabetes, which make hypertension more difficult to treat ([@b6-vhrm-4-1387]; [@b81-vhrm-4-1387]). In the previously described GEMINI trial, carvedilol IR lowered SBP by 18.1 mmHg and DBP by 9.9 mmHg, which was consistent with the 16.9 mmHg and 9.5 mmHg decreases in SBP and DBP, respectively, observed with metoprolol ([@b6-vhrm-4-1387]). At the end of the beta-blocker titration period, 37% and 36% of patients treated with carvedilol IR and metoprolol, respectively, achieved blood pressure goals (\<130/80 mmHg for patients with diabetes) ([@b81-vhrm-4-1387]). It should be noted that patients enrolled in this study were already receiving a stable regimen of antihypertensive therapy with an angiotensin-converting enzyme (ACE) inhibitor or an angiotensin-receptor blocker.

Carvedilol CR has demonstrated efficacy in the treatment of hypertension providing blood pressure control in up to 53% of the clinical patient population, which included patients with uncontrolled hypertension already receiving other classes of antihypertensive agents ([@b77-vhrm-4-1387]). Additionally, based on the results of trials conducted with carvedilol IR, carvedilol CR may provide an equivalent extent of efficacy in more difficult to treat patients such as those patients with hypertension and diabetes.

Heart failure
-------------

Along the cardiovascular continuum, heart failure is a natural progression of uncontrolled hypertension. A recently completed trial in patients with heart failure compared the effects of carvedilol CR with those of carvedilol IR. Coreg: A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study to Compare Effects of Coreg CR and Coreg IR on Ejection Fraction in Subjects With Stable Heart Failure (COMPARE) trial randomized patients with mild to severe heart failure and a left ventricular ejection fraction of 40% (N = 253) to either carvedilol CR (from 10 to 80 mg once daily) or carvedilol IR (from 3.125 to 25 mg twice daily) for up to 8 months ([@b31-vhrm-4-1387]). The primary efficacy endpoint was the change from baseline in left ventricular end-systolic volume index at 6 months. Secondary endpoints included change from baseline in left ventricular remodeling and serum B-type natriuretic peptide, hospitalization for heart failure and all other causes, death from all causes, compliance, and safety and tolerability of carvedilol CR. Full results are not yet published.

The beneficial effects of carvedilol IR have been demonstrated along the spectrum of severity from mild to severe heart failure ([@b25-vhrm-4-1387]). The Australia/New Zealand (ANZ) double-blind trial randomized 415 patients with chronic, stable, mild heart failure to receive either carvedilol IR (from 3.125 mg to 25 mg, as tolerated) or placebo twice daily for 12 months ([@b4-vhrm-4-1387]). Carvedilol IR increased left ventricular ejection fraction from baseline by 5.1% at 12 months and decreased left-ventricular and end-systolic dimensions by 1.7 mm and 3.2 mm, respectively, compared with placebo. After a mean follow-up of 19 months, carvedilol IR decreased the combined risk of death or hospitalization in patients with heart failure risk by 26% versus placebo.

The US Carvedilol Heart Failure Study Group enrolled 1094 patients with mild to severe heart failure in a double-blind, stratified program, assigning patients to 1 of 4 treatment protocols on the basis of their exercise capacity ([@b54-vhrm-4-1387]). The mortality and hospitalization data from these 4 trials were analyzed together and considered together by the Data and Safety Monitoring Board for the trial. Patients were randomized to receive carvedilol IR (from 6.25 to 50 mg, if tolerated) or placebo twice daily and were followed for 6 months (12 months for the mild heart failure group). Compared with placebo, carvedilol IR significantly reduced mortality rates (3.2% versus 7.8%; p \< 0.001), risk of hospitalization for cardiovascular causes (14.1% versus 19.6%; p = 0.036), and the combined endpoint of hospitalization or death (15.8% versus 24.6%; p \< 0.001). The program was stopped early based on the significant improvements in survival with carvedilol IR compared with placebo. This finding is notable as the patients were only followed for an average of 6.5 months, which is a treatment period usually considered too short in duration to observe an effect on mortality and morbidity rates.

The Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study randomized 2289 patients with symptoms of heart failure at rest or on minimal exertion with a left ventricular ejection fraction of \<25% (ie, severe heart failure) to receive either placebo or carvedilol IR, (from 3.125 mg to 25 mg, as tolerated) ([@b56-vhrm-4-1387]). Treatment with carvedilol IR resulted in a 27% reduction of the combined endpoint of death or hospitalization for a cardiovascular reason (p \< 0.0001 versus placebo), as well as a 31% reduction in the combined endpoint of death or hospitalization for heart failure (p \< 0.001 versus placebo). Carvedilol IR treatment also significantly reduced the frequency of serious adverse events, including worsening heart failure, sudden death, cardiogenic shock, and ventricular tachycardia (p = 0.002 versus placebo).

Additionally, over a mean duration of 58 months in the COMET study, significantly fewer deaths occurred in the carvedilol group (512 of 1511 patients; 34%) compared with the metoprolol group (600 of 1518 patients; 40%; p = 0.0017) ([Figure 4](#f4-vhrm-4-1387){ref-type="fig"}) ([@b62-vhrm-4-1387]). Cardiovascular death was less prevalent in the carvedilol group than in the metoprolol group (438 versus 534 patients; p = 0.0004), as were sudden death, circulatory failure, and stroke ([@b62-vhrm-4-1387]; [@b72-vhrm-4-1387]). Results for the combined endpoint of all-cause mortality or all-cause admissions were similar in both groups (74% and 76% of patients for carvedilol IR and metoprolol, respectively). It should be noted that metoprolol tartrate at 50 mg twice daily has not been shown in clinical trials to provide a mortality benefit. However, of note in the metoprolol succinate heart failure trial (MERIT-HF), the mean daily dose was 159 mg daily, which is equivalent to 106 mg daily of metoprolol tartrate ([@b62-vhrm-4-1387]).

Another long-term study that compared carvedilol IR (49 mg daily) with metoprolol tartrate (124 mg daily) in patients with chronic heart failure (N = 150) demonstrated a greater decrease in exercise heart rate with carvedilol than with metoprolol after 13 to 15 months of treatment (p = 0.006) ([@b48-vhrm-4-1387]). In contrast, a recent trial comparing carvedilol IR (32 mg daily) and metoprolol succinate (96 mg daily) in a similar patient population (N = 37) observed a significant increase in exercise heart rate with carvedilol versus metoprolol (135 ± 4 versus 117 ± 6 beats/minute, respectively; p = 0.02), although peak exercise norepinephrine levels were similar (2736 ± 320 versus 2403 ± 372 pg/mL, respectively) ([@b75-vhrm-4-1387]). These findings are of note because attenuation of exercise-induced heart rate is used as a surrogate for the extent of beta 1-adrenergic blockade and possibly to evaluate dosing equivalency. Many reasons may contribute to the results of these trials, including nonequivalent doses or different formulations or durations of treatment.

Post-MI LVD
-----------

Carvedilol is currently the only beta-blocker approved for use in patients with post-MI LVD. The only clinical data available in this patient population is with carvedilol IR. The Carvedilol Post-Infarct Survival Control in LV Dysfunction (CAPRICORN) study investigated the benefits of a beta-blocker (carvedilol IR) in patients with post-MI LVD who were receiving standard therapy. In this double-blind trial, 1959 patients who had experienced an MI and had a left ventricular ejection fraction ≤40% were randomized to receive either carvedilol IR (from 6.25 mg up to 25 mg as tolerated) or placebo twice daily ([@b19-vhrm-4-1387]). The mean follow-up duration was 1.3 years, and 74% of patients achieved the maximum dose of carvedilol IR (25 mg twice daily). In this study, carvedilol IR decreased all-cause mortality by 23% versus placebo ([Figure 5](#f5-vhrm-4-1387){ref-type="fig"}). However, there was no significant difference between groups in the composite endpoint of all-cause mortality or cardiovascular hospital admission. Data from CAPRICORN showed that carvedilol IR has antiar-rhythmic effects post-MI ([@b46-vhrm-4-1387]). Moreover, a substudy from CAPRICORN reported positive effects of carvedilol IR on ventricular remodeling ([@b20-vhrm-4-1387]). The authors speculate that the influence on ventricular remodeling may be a substantial contributing factor to the clinical efficacy observed in patients with post-MI LVD. More recently, Fonarow and colleagues assessed the 30-day outcomes from CAPRICORN. Reductions with carvedilol IR versus placebo were observed in mortality, fatal or nonfatal MI; the composite endpoint of death, nonfatal MI, or cardiac arrest; and the composite endpoint of all-cause mortality or nonfatal MI ([@b24-vhrm-4-1387]).

Based on the CAPRICORN data, the number needed to treat to prevent 1 death for 1 year was 43 ([@b53-vhrm-4-1387]). This compares favorably with data from the atenolol Beta-Blocker Heart Attack Trial (BHAT) showing that 80 patients would need treatment for 1 year to prevent 1 death ([@b53-vhrm-4-1387]). In contrast, the Norwegian Timolol Trial reported that 25 patients needed treatment for 1 year to prevent 1 death ([@b53-vhrm-4-1387]).

Safety and tolerability of carvedilol CR
========================================

The clinical utility of traditional beta-blockers has been limited by concerns regarding negative effects on glucose and lipid metabolism ([@b7-vhrm-4-1387]; [@b10-vhrm-4-1387]) and a high incidence of side effects, including fatigue, erectile dysfunction, and weight gain ([@b10-vhrm-4-1387]). Unlike traditional beta-blockers, the alpha 1-blocking vasodilatory activity with carvedilol does not interfere with glucose and lipid metabolism (discussed previously) and has a positive influence on its tolerability profile.

Carvedilol CR is generally well tolerated across its therapeutic indications ([@b33-vhrm-4-1387]; [@b57-vhrm-4-1387]; [@b77-vhrm-4-1387]). Adverse events reported in clinical trials were consistent with the mechanism of action of carvedilol and the health status of the patient population under evaluation. In the bioequivalence study in patients with hypertension (N = 122), the proportion of patients who experienced an adverse event was lower with carvedilol CR compared with carvedilol IR ([@b33-vhrm-4-1387]). Moreover, headache, orthostatic hypotension, diarrhea, and dizziness occurred more frequently with carvedilol IR than with carvedilol CR ([Table 1](#t1-vhrm-4-1387){ref-type="table"}) ([@b33-vhrm-4-1387]). It must be acknowledged, however, that this was a small study (122 patients) of short duration (approximately 5 weeks). The adverse event profile was comparable between carvedilol IR and carvedilol CR among patients with heart failure or post-MI enrolled in a pharmacokinetics study, with no notable increase in events when patients were switched from carvedilol IR to CR ([@b57-vhrm-4-1387]). In the carvedilol CR hypertension efficacy study, the occurrences of fatigue, dizziness, and headache were comparable between the combined carvedilol dose groups and the placebo group ([@b77-vhrm-4-1387]).

Potential for improving patient adherence to therapy
====================================================

Reducing pill burden
--------------------

Use of multiple concomitant medications in the treatment of hypertension, heart failure, and MI contributes to the polypharmacy that is common among patients receiving carvedilol. Combinations of diuretics, ACE inhibitors, digitalis, glycosides, and beta-blockers are common in the treatment regimen for patients with heart failure. After an MI, guidelines recommend treatment with multiple evidence-based medications, including aspirin, clopidogrel, a statin, an ACE inhibitor, and a beta-blocker. In the field of hypertension, few patients achieve adequate blood pressure control on monotherapy ([@b9-vhrm-4-1387]). In fact, in ALLHAT, a mean of 2 drugs was required to reach blood pressure targets ([@b17-vhrm-4-1387]). Couple these findings with the treatment regimens for common comorbidities (eg, diabetes, coronary artery disease), and the pill burden can become quite substantial.

Both the number of pills taken daily and frequency of dosing affect patient adherence to prescribed therapies, and adherence, in turn, influences clinical outcomes ([@b14-vhrm-4-1387]). In patients with hypertension, lack of adherence has been shown to reduce treatment benefit and increase the risk of poor treatment outcome ([@b28-vhrm-4-1387]). Among patients post-MI, lack of adherence to statins, calcium channel blockers, and beta-blockers significantly increased mortality risk (p = 0.001) ([@b64-vhrm-4-1387]).

One method for reducing pill burden is to design drugs that can be dosed less frequently. One such example is carvedilol CR. Once-daily dosing has been shown to improve adherence ([@b28-vhrm-4-1387]). Data compiled from 76 studies covering a range of therapeutic areas demonstrated that once-daily dosing is associated with the highest adherence rate among various dosing regimens ([@b14-vhrm-4-1387]).The levels of adherence declined as the number of daily doses increased (79% for once daily, 69% for twice daily, 65% for 3 times daily, and 51% for 4 times daily). Moreover, the adherence benefit of once-daily dosing has been specifically observed with a beta-blocker (metoprolol) used for the treatment of hypertension ([@b5-vhrm-4-1387]).

The Compliance and Quality of Life Study Comparing Once-Daily Controlled-Release Carvedilol CR and Twice-Daily Immediate-Release Carvedilol IR in Patients with Heart Failure (CASPER) trial was based on the assumptions that adherence to the medication regimen would be 75% with twice-daily medication and 90% with once-daily medication ([@b32-vhrm-4-1387]). Patients with mild to severe heart failure and a left ventricular ejection fraction of 40% or less were randomized to either a double-blind arm (morning carvedilol CR plus an evening placebo versus morning and evening carvedilol IR) or to an open-label arm (carvedilol CR). However, preliminary results demonstrated no difference in patient adherence between once-daily and twice-daily regimens (88% versus 89%) ([@b74-vhrm-4-1387]; [@b12-vhrm-4-1387]). These results may be explained, in part, by the consideration that patient adherence may be higher in clinical trials than in the community setting. Indeed, the carvedilol IR recipients in this trial had a higher than anticipated compliance rate.

Another option for reducing pill burden is to reduce the number of individual pills through use of a fixed-dose combination (FDC). Fixed-dose combinations have become increasingly common in the field of hypertension because of the frequent need for multiple concomitant antihypertensives to control blood pressure. Fixed-dose combinations may also work synergistically, resulting in a lower total dose of each individual drug ([@b63-vhrm-4-1387]). The ability to reduce drug doses can also reduce the risk of side effects. Use of an FDC may also have positive effects on patient adherence. In a study comparing adherence between patients treated with an FDC (n = 11,925) and patients treated with a free-drug regimen (n = 8317), those receiving an FDC had a significantly decreased risk of nonadherence (p \< 0.0001) ([@b9-vhrm-4-1387]).

An FDC consisting of carvedilol and the ACE inhibitor lisinopril is currently in development. The Coreg and Lisinopril Combination Therapy in Hypertensive Subjects (COSMOS) trial is assessing the efficacy and safety of a carvedilol/lisinopril FDC (ClinicalTrials.gov Identifier: NCT00347360). COSMOS is a randomized, double-blind, double-dummy, parallel-group trial employing a 4 × 4 factorial design that will evaluate carvedilol (20, 40, or 80 mg daily) alone, lisinopril (10, 20, or 40 mg daily) alone, and all permutations of the combined drugs in patients with hypertension.

Quality of life and patient satisfaction
----------------------------------------

Quality of life is more difficult to assess than concrete measures such as blood pressure or mortality. If improved tolerability and reduced risk for side effects were considered, one would anticipate an improvement in this category with carvedilol as appraised relative to traditional beta-blockers.

Some clinical trials have revealed improvements in patient-reported quality-of-life assessments. The effects of carvedilol IR on patient global assessment were reported in patients with heart failure ([@b56-vhrm-4-1387]). In a study of 2289 patients with heart failure, patients receiving treatment with carvedilol were more likely to show moderate or marked improvement and less likely to show moderate or marked worsening versus placebo. In the previously described COMET study, a patient-completed, self-assessment scoring system that was evaluated every 4 months of treatment demonstrated a significantly improved self-score for patients treated with carvedilol (p \< 0.0068) ([@b15-vhrm-4-1387]).

A prespecified secondary analysis of the GEMINI study used the Diabetes Symptom Checklist to record patient-reported occurrences of diabetes-related symptoms in 8 domains, namely psychology (fatigue), psychology (cognitive), neuropathy (pain), neuropathy (sensory), cardiology, ophthalmology, hyperglycemia, and hypoglycemia ([@b45-vhrm-4-1387]). After 5 months of treatment, the results significantly favored carvedilol over metoprolol tartrate in overall maintenance score (p = 0.02), hypoglycemia symptoms (p = 0.02), and hyperglycemia symptoms (p = 0.005).

Conclusions
===========

The varied mechanisms of action of carvedilol allow it to be an effective treatment of hypertension, heart failure, and post-MI LVD, with less of the metabolic and tolerability concerns associated with traditional beta-blockers. The key difference from the majority of beta-blockers appears to be vasodilation mediated by alpha 1-adrenergic receptor blockade, which decreases total peripheral resistance ([@b60-vhrm-4-1387]). Furthermore, carvedilol's antioxidant and anti-inflammatory effects may provide additional car-dioprotective effects beyond that of traditional beta-blockers ([@b18-vhrm-4-1387]). Carvedilol has a long history and a proven track record in the treatment of hypertension and cardiac dysfunction. The once-daily formulation of carvedilol provides a more convenient option and may confer an adherence benefit over the twice-daily formulation in conditions traditionally prone to noncompliance such as hypertension and post-MI LVD.
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![Mean steady state concentration-time profiles for S(−) and R(+) enantiomers for carvedilol immediate-release and controlled-release. Reprinted from [@b33-vhrm-4-1387]. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension. *Am J Cardiol*, 98:17L--26L. Copyright © 2006, with permission from Elsevier.\
**Abbreviations:** IR, immediate release, CR, controlled release, QD, once daily.](vhrm-4-1387f1){#f1-vhrm-4-1387}

![Glycosylated hemoglobin (HbA~1c~) at baseline and each maintenance month by treatment in GEMINI. Reproduced with permission from [@b6-vhrm-4-1387]. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA*, 292:2227--36. Copyright © 2004, American Medical Association. All Rights Reserved.\
**Note:** Data are means ± standard deviations.](vhrm-4-1387f2){#f2-vhrm-4-1387}

![Controlled-release carvedilol in hypertension. Adapted from Weber MA, Sica DA, Tarka EA, et al Controlled-release carvedilol in the treatment of essential hypertension. *Am J Cardiol*, 98:32L--38L. Copyright © 2006, with permission from Elsevier.\
**Abbreviations:** CR, controlled release, DBP, diastolic blood pressure, SBP, systolic blood pressure.\
**Note:** Data are change from baseline in model-adjusted peak (3 to 7 hours) diastolic blood pressure and systolic blood pressure measured by ambulatory blood pressure monitoring. \*p \< 0.05, ^†^p \< 0.001, ^‡^p \< 0.0001, based on pair-wise comparison of change from baseline with placebo.](vhrm-4-1387f3){#f3-vhrm-4-1387}

![Kaplan-Meier estimates of all-cause mortality in COMET. Reprinted from Poole-Wilson PA, Swedberg K, Cleland JG, et al Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. *Lancet*, 362:7--13. Copyright © 2003, with permission from Elsevier.](vhrm-4-1387f4){#f4-vhrm-4-1387}

![Kaplan-Meier estimates of event-free survival in CAPRICORN. Reprinted from Dargie HJ, for the CAPRICORN Investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. *Lancet*, 357:1385--90. Copyright © 2001, with permission from Elsevier.](vhrm-4-1387f5){#f5-vhrm-4-1387}

###### 

Treatment-related adverse events with IR and CR carvedilol**[a](#tfn1-vhrm-4-1387){ref-type="table-fn"}**

  Variable                              Regimen                                                             
  ------------------------------------- ----------- ---------- ----------- ----------- --------- ---------- -----------
  Patients exposed (n)                  65          26         50          67          26        51         63
  Patients with adverse events, n (%)   18 (27.7)   5 (19.2)   14 (28.0)   17 (25.4)   1 (3.8)   7 (13.7)   16 (25.4)
  Adverse event, n (%)                                                                                      
    Headache                            11 (16.9)   3 (11.5)   10 (20)     6 (9.0)     1 (3.8)   5 (9.8)    7 (11.1)
    Orthostatic hypotension             3 (4.6)     2 (7.7)    2 (4.0)     3 (4.5)     0 (0)     2 (3.9)    5 (7.9)
    Dizziness                           3 (4.6)     2 (7.7)    3 (6.0)     1 (1.5)     0 (0)     0 (0)      4 (6.3)
    Fatigue                             0 (0)       0 (0)      0 (0)       1 (1.5)     0 (0)     0 (0)      2 (3.2)
    Somnolence                          0 (0)       0 (0)      1 (2.0)     2 (3.0)     0 (0)     0 (0)      0 (0)
    Asthenia                            2 (3.1)     0 (0)      0 (0)       0 (0)       0 (0)     0 (0)      0 (0)
    Dyspepsia                           1 (1.5)     0 (0)      0 (0)       1 (1.5)     0 (0)     0 (0)      0 (0)
    Edema, peripheral                   1 (1.5)     0 (0)      0 (0)       0 (0)       0 (0)     1 (2.0)    0 (0)
    Hypotension                         1 (1.5)     0 (0)      0 (0)       1 (1.5)     0 (0)     0 (0)      0 (0)

Only the most commonly reported adverse events (considered by the investigator to be related to study medication) are listed.

Adverse events attributed to any dose of carvedilol IR or carvedilol CR include events that were reported by patients in any treatment group who were receiving the designated regimen (sessions 1--4), adverse events that occurred in the downtitration period are not included (session 5).

Placebo group included the downtitration period (session 5) for the 2 low-dose groups that previously received carvedilol in sessions 1--4.

**Abbreviations:** CR, controlled release, IR, immediate release, BID, twice daily, QD, once daily.

Reprinted from Henderson LS, Tenero DM, Baidoo CA, et al Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension, *Am J Cardiol*, 98:17L--26L. Copyright © 2006, with permission from Elsevier.
